ACTIVATE Trial: Controlling COPD Symptoms to Improve Physical Activity and Change Outcome

PCSK9 Inhibitors Outcomes Data: Definitive CV Protection

Reduced All-Cause Death Suggests SGLT-2 Inhibitors May Be Part of New Anti-Diabetes Standard

Progress in Myelofibrosis: Early Use of Targeted Therapy May Extend Life Expectancy

Upward PCSK9 Inhibitor Dose Titration Uncommonly Required to Reach Goal in Challenging Patients

New Data Emphasize the Therapeutic Value of Biologics in Control of Severe Eosinophilic Asthma

Results From Multinational Phase 3 Trials: Benefit of Depleting Eosinophils in Severe Asthma Reinforced with New Biologic

PCSK9 Inhibitors Required to Reach LDL-C Goals in Many High-risk Patients

High Rates of Adherence: New Opportunities for Indefinite HIV Control

Efficacy and Safety of PCSK9 Inhibitors Now Measured In Years with No Change in Scale of Clinical Benefit

Landmark FLAME Data Support Guideline Change in COPD Patients with a History of Exacerbations